20 commercial payer policies list J2502. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
20 policies from 12 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2502 |
|---|---|---|
| Pasireotide injection (Signifor LAR)Effective 01/01/2019 - 08/31/2019 | Jan 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Pasireotide injection (Signifor LAR)Effective 06/01/2022 - 05/31/2023 | Jun 1, 2022 | Prior auth requiredInferred from policy title |
| Pasireotide injection (Signifor LAR)Effective 07/01/2021 - 05/31/2022 | Jul 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Pasireotide injection (Signifor LAR)Effective 08/01/2020 - 06/30/2021 | Aug 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Pasireotide injection (Signifor LAR)Effective 09/01/2019 - 07/31/2020 | Sep 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Signifor LAR (pasireotide) Injectable Suspension | Not recorded | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Signifor LAR (pasireotide) Injectable SuspensionEffective 05/01/2024 - 04/30/2025 | May 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Signifor LAR (pasireotide) Injectable SuspensionEffective 05/01/2025 - 04/30/2026 | May 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Signifor LAR (pasireotide) Injectable SuspensionEffective 06/01/2023 - 04/30/2024 | Jun 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2502 |
|---|---|---|
| Somatostatin Analogs | Jul 1, 2023 | Covered |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Pasireotide (e.g., Signifor or Signifor LAR) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Pasireotide (Signifor LAR) | Jul 1, 2015 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Pasireotide (Signifor LAR, Singifor); CP.PHAR.332 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Somatostatin analogues for acromegaly (Sandostatin LAR, Somatuline Depot, Signifor LAR, Somavert, Lanreotide) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Sandostatin, Sandostatin LAR depot (Octreotide), Somatuline Depo (lanreotide), Signifor LAR (pasireotide) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2502 |
|---|---|---|
| 00384 pasireotide Injection (Signifor/Signifor LAR) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Signifor LAR (pasireotide) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Somatostatin Analogs | Apr 1, 2026 | Covered |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Somatostatin Analogs | Apr 1, 2026 | Covered |
| Policy | Effective | Status of J2502 |
|---|---|---|
| Somatostatin Analogs | Apr 1, 2026 | Covered |